These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36305305)

  • 1. Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.
    Shah H; Ravi P; Sonpavde G; Jacene H
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1163-1175. PubMed ID: 36305305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.
    Keam SJ
    Mol Diagn Ther; 2022 Jul; 26(4):467-475. PubMed ID: 35553387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
    Liu X; Fang GC; Lu H; Shi ZD; Chen ZS; Han CH
    Drugs Today (Barc); 2023 Jan; 59(1):37-49. PubMed ID: 36811416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
    Fallah J; Agrawal S; Gittleman H; Fiero MH; Subramaniam S; John C; Chen W; Ricks TK; Niu G; Fotenos A; Wang M; Chiang K; Pierce WF; Suzman DL; Tang S; Pazdur R; Amiri-Kordestani L; Ibrahim A; Kluetz PG
    Clin Cancer Res; 2023 May; 29(9):1651-1657. PubMed ID: 36469000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.
    Ramnaraign B; Sartor O
    Oncologist; 2023 May; 28(5):392-401. PubMed ID: 36806966
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Chi KN; Yip SM; Bauman G; Probst S; Emmenegger U; Kollmannsberger CK; Martineau P; Niazi T; Pouliot F; Rendon R; Hotte SJ; Laidley DT; Saad F
    Curr Oncol; 2024 Mar; 31(3):1400-1415. PubMed ID: 38534939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer.
    Soon YY; Marschner IC; Schou M; Hofman MS; Emmett L; Davis ID; Stockler MR; Martin AJ
    JAMA Netw Open; 2024 Sep; 7(9):e2433863. PubMed ID: 39287944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life and pain outcomes with [
    Fizazi K; Herrmann K; Krause BJ; Rahbar K; Chi KN; Morris MJ; Sartor O; Tagawa ST; Kendi AT; Vogelzang N; Calais J; Nagarajah J; Wei XX; Koshkin VS; Beauregard JM; Chang B; Ghouse R; DeSilvio M; Messmann RA; de Bono J
    Lancet Oncol; 2023 Jun; 24(6):597-610. PubMed ID: 37269841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [
    Satapathy S; Sahoo RK; Bal C
    J Nucl Med; 2023 Aug; 64(8):1266-1271. PubMed ID: 37169534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New drugs approval: Lutetium-PSMA in metastatic castration-resistant prostate cancer].
    Roulleaux Dugage M; Schlürmann F
    Bull Cancer; 2023 Jun; 110(6):600-602. PubMed ID: 37059642
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Mehrens D; Kramer KKM; Unterrainer LM; Beyer L; Bartenstein P; Froelich MF; Tollens F; Ricke J; Rübenthaler J; Schmidt-Hegemann NS; Herlemann A; Unterrainer M; Kunz WG
    J Natl Compr Canc Netw; 2023 Jan; 21(1):43-50.e2. PubMed ID: 36634610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The VISION Forward: Recognition and Implication of PSMA-/
    Jadvar H
    J Nucl Med; 2022 Jun; 63(6):812-815. PubMed ID: 34933889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Drug for Metastatic Castration-Resistant Prostate Cancer.
    Aschenbrenner DS
    Am J Nurs; 2022 Jul; 122(7):27. PubMed ID: 35736599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer.
    Wang JS; Wong T; Wu KA; Mullikin TC; Armstrong A
    BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38395466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurologic Symptoms After
    Belge Bilgin G; Burkett BJ; Bilgin C; Orme JJ; Childs DS; Rincon MM; Abdelrazek AS; Johnson DR; Johnson GB; Kwon ED; Sartor O; Kendi AT
    J Nucl Med; 2024 Sep; 65(9):1402-1408. PubMed ID: 39089816
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Satapathy S; Mittal BR; Sood A; Das CK; Mavuduru RS; Goyal S; Shukla J; Singh SK
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1754-1764. PubMed ID: 34842950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
    Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
    Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes of
    Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
    J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
    [No Abstract]   [Full Text] [Related]  

  • 20. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.